| Literature DB >> 35146043 |
Enrique Bernal1, Monica Martinez1, José Antonio Campillo2, Gabriel Puche1, Carlos Baguena1, Cristina Tomás1, Amaya Jimeno3, Maria Jose Alcaraz1, Antonia Alcaraz1, Angeles Muñoz1, Eva Oliver1, Alejandro de la Torre1, Irene Marín4, Alfredo Cano1, Alfredo Minguela2.
Abstract
BACKGROUND: Physical activity has anti-inflammatory effects and reduces morbidity and mortality in the general population, but its role in the clinical, CD4/CD8 ratio, and immune activation status of HIV-infected patients has been poorly studied.Entities:
Keywords: CD4/CD8 ratio; immunoactivation; physical activity
Year: 2021 PMID: 35146043 PMCID: PMC8826224 DOI: 10.1093/ofid/ofab654
Source DB: PubMed Journal: Open Forum Infect Dis ISSN: 2328-8957 Impact factor: 4.423
Patient Characteristics According to Physical Activity
| Biological Characteristics | Sedentary/Low Intensity (n = 77) | Moderate Intensity (n = 78) |
|
|---|---|---|---|
| Age, mean (SD), y | 50.03 (10.28) | 47.59 (10.72) | .151 |
| Sex, male, No. (%) | 58 (75.3) | 59 (75.6) | 1.000 |
| BMI, median [IQR], kg/m2 | 27.91 [24.34–29.32] | 25.21 [23.48–28.42] | .024 |
| C hepatitis virus antibodies, No. (%) | 18 (23.7) | 12 (16.0) | .327 |
| Parameters related to HIV infection | |||
| Transmission, No. (%) | |||
| Heterosexual | 36 (48.0) | 23 (29.9) | .102 |
| Homosexual/bisexual | 26 (34.7) | 41 (53.2) | |
| Intravenous drug users | 10 (13.3) | 10 (13.0) | |
| Others/unknown | 3 (4.0) | 3 (3.9) | |
| CDC HIV stage, No. (%) | |||
| A | 21 (32.8) | 36 (52.9) | .046 |
| B | 24 (37.5) | 21 (30.9) | |
| C | 19 (29.7) | 11 (16.2) | |
| ART, No. (%) | |||
| Protease inhibitor | 27 (35.1) | 13 (16.9) | .017 |
| NNRTI | 19 (24.7) | 33 (42.9) | .027 |
| Integrase inhibitor | 40 (51.9) | 38 (49.4) | .872 |
| Other ART combinations | 17 (22.4) | 14 (18.2) | .658 |
| Time on ART, median [IQR], y | 3.70 [2.21–9.67] | 4.49 [2.49–8.00] | .744 |
| CD4 nadir, median [IQR], cells/mL | 232.5 [111.5–367.2] | 290.0 [128.5–429.0] | .217 |
| HIV viral load <20 copies/mL, No. (%) | 69 (89.6) | 75 (97.4) | .102 |
| CD4 T cell, median [IQR], cells/µL | 711.0 [433.0–960.0] | 750.0 [549.0–927.0] | .212 |
| CD8 T cell, median [IQR], cells/µL | 947.0 [713.0–1204] | 777.0 [563.0–1064] | .018 |
| CD4/CD8 ratio, median [IQR] | 0.72 [0.42–0.98] | 0.96 [0.64–1.22] | .001 |
| Biochemical parameters | |||
| Glucose, median [IQR], mg/dL | 96.0 [86.0–106.0] | 91.0 [85.0–97.0] | .024 |
| Total cholesterol, median [IQR], mg/dL | 192.0 [164.0–223.0] | 175.0 [159.0–218.0] | .106 |
| LDL cholesterol, median [IQR], mg/dL | 112.0 [88.5–136.5] | 108.0 [85.0–131.0] | .765 |
| HDL cholesterol, median [IQR], mg/dL | 48.00 [40.00–56.00] | 48.0 [41.0–54.0] | .823 |
| Triglycerides, median [IQR], mg/dL | 132.0 [101.0–195.0] | 98.0 [78.0–146.0] | .002 |
| Creatinine, median [IQR], mg/dL | 0.89 [0.81–1.04] | 0.85 [0.77–0.99] | .462 |
| Cardiovascular risk factors | |||
| Type 2 diabetes, No. (%) | 6 (7.8) | 2 (2.6) | .268 |
| Hypertension, No. (%) | 15 (19.5) | 12 (15.4) | .645 |
| Dyslipidemia, No. (%) | 29 (37.7) | 26 (33.3) | .693 |
| Smoker, No. (%) | |||
| Nonsmoker | 30 (39.0) | 40 (51.3) | .088 |
| Current smoker | 44 (57.1) | 38 (48.7) | |
| Previous smoker | 3 (3.9) | 0 (0.0) | |
| Drink alcohol, No. (%) | 36 (46.8) | 42 (53.8) | .66 |
| Coronary heart disease, No. (%) | 5 (6.6) | 1 (1.3) | .200 |
| Stroke, No. (%) | 1 (1.3) | 1 (1.3) | 1.000 |
| Framingham Risk Score, median [IQR] | 3.00 [2.00–4.25] | 2.50 [1.00–4.00] | .380 |
| Metabolic syndrome, No. (%) | 24 (32.4) | 10 (13.3) | .010 |
| HOMA, median [IQR] | 3.01 [1.60–5.38] | 1.93 [1.41–2.54] | .002 |
Abbreviations: ART, antiretroviral therapy; BMI, body mass index; CDC, Centers for Disease Control and Prevention; HDL, high-density lipoprotein; HOMA, homeostatic model assessment; IQR, interquartile range; LDL, low-density lipoprotein; NNRTI, non-nucleoside retroviral transcriptase inhibitor.
Immunological Characteristics According to Physical Activity
| Sedentary or Low Intensity (n = 77) | Moderate Intensity (n = 78) |
| |
|---|---|---|---|
| Leukocyte subsets, median [IQR] | |||
| Leukocytes, cells/µL | 5700 [4400–7300] | 5600 [3500–6792] | .247 |
| Lymphocytes, % | 32.01 [23.71–37.74] | 28.12 [23.29–36.69] | .324 |
| Monocytes, % | 7.17 [5.88–8.80] | 7.47 [6.10–8.98] | .930 |
| Neutrophils, % | 57.09 [50.58–63.14] | 59.02 [51.34–64.81] | .462 |
| Eosinophils, % | 1.89 [1.26–3.11] | 2.38 [1.26–3.13] | .379 |
| Lymphocyte subsets, median [IQR], % | |||
| B lymphocytes CD19+ | 12.57 [7.57–17.47] | 11.36 [8.84–17.11] | .797 |
| NK lymphocytes CD16+ | 10.33 [5.04–13.77] | 9.29 [6.44–16.47] | .394 |
| T lymphocytes CD3+ | 67.77 [62.63–75.57] | 69.34 [60.72–75.45] | .986 |
| T lymphocytes CD3+CD4+ | 26.37 [18.37–31.85] | 29.14 [24.21–34.18] | .016 |
| T lymphocytes CD3+CD8+ | 39.94 [35.19–46.05] | 35.63 [29.66–43.38] | .011 |
| T lymphocytes CD4+CD8+ | 0.64 [0.36–1.10] | 0.49 [0.31–0.78] | .029 |
| Expression of activation markers, median [IQR], % | |||
| CD4+CD86+ T cells | 2.29 [1.16–6.16] | 1.58 [0.93–3.68] | .045 |
| CD8+CD86+ T cells | 1.87 [1.04–5.62] | 1.42 [0.89–2.57] | .067 |
| CD16+CD86+ NK cells | 2.21 [1.24–5.15] | 1.79 [0.78–3.65] | .086 |
| CD4+HLA-DR+ T cells | 10.89 [6.75–22.16] | 9.26 [4.99–14.00] | .011 |
| CD8+HLA-DR+ T cells | 20.13 [13.15–28.93] | 15.98 [8.62–24.70] | .048 |
| CD16+HLA-DR+ NK cells | 13.04 [6.95–27.55] | 9.63 [4.99–17.01] | .026 |
| Expression of HLA-DR, median [IQR], MFI | |||
| In monocytes | 7045 [4783–10 205] | 6444 [4936–8962] | .444 |
| In CD19+ B lymphocytes | 14 328 [10 057–18 175] | 12 793 [8190–16 947] | .148 |
| In CD4+ T lymphocytes | 599 [406–1083] | 466 [258–673] | .001 |
| In CD8+ T lymphocytes | 542 [327–842] | 400 [242–739] | .048 |
| Expression of CD86, median [IQR], MFI | |||
| In monocytes | 1513 [1252–1989] | 1480 [1279–1950] | .500 |
| In CD4+ T lymphocytes | 119 [75–219] | 90 [34–151] | .014 |
| In CD8+ T lymphocytes | 79 [49–146] | 61 [29–121] | .026 |
No differences in CD28 and CD38 expression were observed in T, B, or NK cells.
Abbreviations: IQR, interquartile range; MFI, mean fluorescence intensity; NK, natural killer.
Variables Associated With CD4/CD8 Ratio <0.8
| Multivariable Analysis | |||
|---|---|---|---|
| OR | 95% CI |
| |
| ART type | 2.697 | 0.667–10.91 | .360 |
| Time on ART | 0.980 | 0.929–1.040 | .560 |
| Sedentary or low physical activity | 2.180 | 1.030–4.600 | .042 |
| CD4+ lymphocyte T nadir | 1.005 | 1.003–1.007 | .001 |
| CD8+CD38+ T cells, % | 1.270 | 1.070–1.500 | .006 |
| CD4+DR+ T cells, % | 1.018 | 0.980–1.050 | .355 |
Abbreviations: ART, antiretroviral therapy; OR, odds ratio.
Figure 1.CD4/CD8 ratio recovery according to physical activity. Box plots showing the evolution of CD4/CD8 ratio according to intensity of physical activity at 3 different moments: 2 years before the final evaluation (baseline), 1 year before the final evaluation (middle), and final . Statistical analysis was performed with mixed analysis of variance.
Figure 2.INSTI- and NNRTI-based ART regimens could favor CD4/CD8 ratio recovery when associated with moderate/intense physical activity. Box plots show CD4/CD8 ratio for the 3 types of ART treatments: PI-, NNRTI-, and INSTI-based regimens. Statistical analysis was performed with mixed analysis of variance. Abbreviations: ART, antiretroviral therapy; INSTI, integrase strand transfer inhibitor; NNRTI, non-nucleoside retroviral transcriptase inhibitor; PI, protease inhibitor.